RAVE RTSM DRIVES GREATER VALUE AND FLEXIBILITY ON MEDIDATA'S UNIFIED PLATFORM

UNLOCK THE POWER OF RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT ON THE MEDIDATA RAVE CLINICAL CLOUD

- Simplified implementation and execution
- Extensive and flexible supply management
- Elimination of reconciliation
- Reduction of risk
- Robust data ingestion to one data repository

COMPREHENSIVE RANDOMIZATION AND SUPPLY MANAGEMENT

Rave RTSM has comprehensive, pre-validated features needed for complex clinical trials with advanced dosing schedules, cohort management, end-to-end supply tracking and accountability, and real-time reporting.

Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective owners. Copyright 2020 Medidata Solutions, Inc., a Dassault Systèmes company
RAVE RTSM DRIVES GREATER VALUE AND FLEXIBILITY ON A UNIFIED PLATFORM

TRANSFORMING RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT

OPERATIONAL MANAGEMENT
- Rapid data insights enable study teams to make quicker informed decisions
- Execute mid study changes efficiently using Edit Live Design feature
- Faster User Acceptance Testing (UAT)

SUPPLY MANAGEMENT
- Drug Pooling reduces packaging waste and shipping costs
- Drug Supply Accountability
- Supply Integration Service
- Enables real-time changes to supply plans

TOP CRO DRAMATICALLY INCREASED RAVE RTSM USE

“Over the last 6 years, we have implemented over 130 studies in Rave RTSM and this number is growing every week. We use the Rave RTSM for all aspects of the clinical study related to a randomization drug distribution and assignment, and also, of course, unmasking. For most of the studies, we use the existing built-in and validated functionality of RTSM.”

— Voitek Gradziuk, Principal Solutions Consultant, SYNEOS HEALTH

20K
In Savings Per Protocol Amendment

34%
Reduction in Shipping Costs

SIGNIFICANT REDUCTION IN KEY PERFORMANCE INDICATOR CYCLE TIMES

>50%
Reduction in UAT Cycle Time

15%
Reduction in Data Entry Cycle Time

50–75%
Reduction in Mid-Study Change Cycle Time

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data.

Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers.

Discover more at www.medidata.com and follow us @medidata. The Operating System for Life Sciences™.

info@medidata.com | +1 866 515 6044